pharma · Diabetic Macular Edema · Hypercholesterolemia · REGN
Regeneron UK
Regeneron UK Limited
Regeneron UK is a pharma organization headquartered in Tarrytown, USA. It trades on NYSE under ticker REGN. Primary therapeutic focus areas include Diabetic Macular Edema, Hypercholesterolemia, Asthma, Macular Degenerati
Company details
- Status
- Public
- HQ
- Tarrytown, USA
- Employees
- 16,715
- Programs
- 493
- Drugs
- 98
- Patents
- 837
REGN7544
Phase 2 · small molecule · Sepsis-Induced Hypotension
REGN7544 for Sepsis-Induced Hypotension is a Phase 2 program (small_molecule) at Regeneron UK Limited with 1 ClinicalTrials.gov record(s).
Internal code R7544-SIH-2435
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Regeneron UK Limited
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Sepsis-Induced Hypotension
- Status
- completed
- Trials
- 1